SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (198)5/5/2004 6:36:13 PM
From: Area51  Read Replies (1) of 255
 
<<Could be that this is limited to T1, as they have substantially more circulating abs at baseline. However, the T2 study originally planned to start this year will be delayed until they figure this out.>>

I gather this is the critical question. Since the market has cut ARDM price in half it seems to say that there is a 50% chance that the product is still marketable to type 2 diabetics (which are more than 90% of all diabetics or so I understand).

Since you sold I guess you think that there is less than a 50% chance that the product will be marketable to type 2 diabetics?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News